Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 2031-2034, 2007; 10.1373/clinchem.2007.091140
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shaikh, N. A.
Right arrow Articles by Drebot, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Shaikh, N. A.
Right arrow Articles by Drebot, M.
Related Collections
Right arrow Clinical Immunology
Right arrow Infectious Disease
(Clinical Chemistry. 2007;53:2031-2034.)
© 2007 American Association for Clinical Chemistry, Inc.

Abstracts of Oak Ridge Posters

Development of a Novel, Rapid, and Sensitive Immunochromatographic Strip Assay Specific for West Nile Virus (WNV) IgM and Testing of Its Diagnostic Accuracy in Patients Suspected of WNV Infection

Nisar A. Shaikh1,2,a, Jun Ge2, Yi-Xue Zhao2, Paul Walker2 and Mike Drebot3

(1 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; 2 Spectral Diagnostics, Inc., Toronto, Ontario, Canada; 3 National Microbiology Laboratory, Winnipeg, Manitoba, Canada;

aaddress correspondence to this author at: 135-2 The West Mall, Toronto, Ontario, M9C 1C2 Canada; fax 1-416-626-7383, e-mail nshaikh@spectraldx.com)

The first 300 words of the full text of this article appear below.

The West Nile virus (WNV), detected in the Western hemisphere in 1999, has since spread rapidly across North America into all 48 continental states of the US, 7 Canadian provinces, many Latin American countries, and throughout Mexico. More than 24 000 people in the US have tested positive for WNV infection; 9845 of these cases resulted in serious neuroinvasive disease and more than 959 were fatal (1). Guidelines for surveillance, prevention, and control of WNV are available(2).

WNV, a member of the Flaviviridae family, belongs to the Japanese encephalitis serocomplex that includes Japanese encephalitis and St. Louis encephalitis viruses (3). WNV is transmitted to humans by mosquitoes. The transmission cycle involves mosquitoes and birds. In rare instances, the virus may be transmitted from human to human through organ donation or blood transfusion or from pregnant mother to fetus(4)(5)(6). WNV infections in a pediatric population have also been reported(7). Many patients remain asymptomatic or have only mild symptoms. Others report having fatigue, rash, fever, headache, and muscle weakness and may require hospitalization(8). The more severe form of the disease is meningoencephalitis manifested by typical signs of central nervous system infection and, in a minority of cases, development of a flaccid paralysis(9).

Symptomatic patients will demonstrate an early antibody response of the IgM type during the 1st 4 days of illness, and nearly all patients will have detectable IgM antibodies by 7 to 8 days after the onset of illness (10). WNV-specific serum IgG is detectable by 3 weeks postinfection(11). The virus itself is usually no longer detectable by the time WNV-specific serum IgM appears, although both IgM and IgG may persist for more than a year(12). Laboratory-based . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.